Literature DB >> 20567589

Hepatitis C Virus Therapy-related Skin Manifestations.

Brett E Fortune, Shayla Francis, Lisa M Forman.   

Abstract

Entities:  

Year:  2010        PMID： 20567589      PMCID： PMC2886495     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  28 in total

1.  Effects of corticosteroids on HCV infection.

Authors:  N Magy; B Cribier; C Schmitt; B Ellero; D Jaeck; K Boudjema; P Wolf; N Labouret; M Doffoel; A Kirn; F Stoll-Keller
Journal:  Int J Immunopharmacol       Date:  1999-04

2.  Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment.

Authors:  F Vázquez-López; J A Manjón-Haces; R Pérez-Alvarez; N Pérez-Oliva
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

3.  Generalized exfoliative dermatitis induced by interferon alfa.

Authors:  Luca Gallelli; Maria Ferraro; Gaetano F Mauro; Giovambattista De Sarro
Journal:  Ann Pharmacother       Date:  2004-11-02       Impact factor: 3.154

Review 4.  Overview of hepatitis C and skin.

Authors:  Connie M Chung; Julia R Nunley
Journal:  Dermatol Nurs       Date:  2006-10

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.

Authors:  G T Everson; L Balart; S S Lee; R W Reindollar; M L Shiffman; G Y Minuk; P J Pockros; S Govindarajan; E Lentz; E J Heathcote
Journal:  Aliment Pharmacol Ther       Date:  2008-01-17       Impact factor: 8.171

7.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

8.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Antiviral action of ribavirin in chronic hepatitis C.

Authors:  Jean-Michel Pawlotsky; Harel Dahari; Avidan U Neumann; Christophe Hezode; Georgios Germanidis; Isabelle Lonjon; Laurent Castera; Daniel Dhumeaux
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682
View more
  1 in total

Review 1.  Hepatitis C virus as a systemic disease: reaching beyond the liver.

Authors:  Kirat Gill; Hasmik Ghazinian; Richard Manch; Robert Gish
Journal:  Hepatol Int       Date:  2015-12-10       Impact factor: 6.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.